Literature DB >> 9972866

Clinical and molecular characteristics of Japanese Gaucher disease.

Y Eto1, H Ida.   

Abstract

Clinical signs and symptoms of Gaucher disease are more severe in Japanese than in Jewish and other non-Japanese patients. A higher percentage of bone crises and splenectomy was demonstrated by Japanese patients, and there were five fatalities among patients with type 1 Gaucher disease. Additionally, neonatal Gaucher disease, clinically characterized by hydrops foetalis, was observed. Japanese patients with type 2 and type 3 disease also demonstrate clinical heterogeneity. About 100 alleles of patients with Japanese Gaucher disease were examined for genotype determination with the PCR and SSCP methods. About 18 different mutations, including several novel mutations in Japanese patients, were identified. The most common mutations in Japanese patients were 1448C(L444P), accounting for 41 (41%) of alleles. The second most prevalent mutation was 754A(F2131), accounting for 14 (14%) of alleles. Other alleles identified included the 1324C, IVS2 and other mutations. Unidentified alleles comprised 16% of the total number of alleles studied. To date, neither the 1226G (N370S) nor the 84GG mutation has been identified in the Japanese population, although these mutations account for about 70% and 10% of the mutations in Jewish and other non-Japanese populations, respectively. The phenotype-genotype correlation in Japanese patients is more complex compared with that of the Jewish population. In Japanese patients, the 1448C mutation, in either heteroallelic or homoallelic forms, exhibits both neurological and non-neurological phenotypes. Japanese patients with the 754A mutation also exhibit both neuronopathic and non-neuronopathic disease. On the other hand, patients with the D409H mutation show only type 3 neurological disease, and those with the 1447-1466 del 20 ins TG mutation have the severe, neonatal neurological form of Gaucher disease. The 1503T allele was present only in patients with type 1 non-neurological disease. However, since this correlation was observed only in young patients, we do not as yet know the final phenotypic outcome of this mutation. Probably, Japanese patients with Gaucher disease have few mutations that exhibit non-neurological signs and symptoms.

Entities:  

Mesh:

Year:  1999        PMID: 9972866     DOI: 10.1023/a:1022553819241

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  25 in total

1.  Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene.

Authors:  V L Tybulewicz; M L Tremblay; M E LaMarca; R Willemsen; B K Stubblefield; S Winfield; B Zablocka; E Sidransky; B M Martin; S P Huang
Journal:  Nature       Date:  1992-06-04       Impact factor: 49.962

2.  Genetic heterogeneity in type 1 Gaucher disease: multiple genotypes in Ashkenazic and non-Ashkenazic individuals.

Authors:  S Tsuji; B M Martin; J A Barranger; B K Stubblefield; M E LaMarca; E I Ginns
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

3.  Prediction of severity of Gaucher's disease by identification of mutations at DNA level.

Authors:  A Zimran; J Sorge; E Gross; M Kubitz; C West; E Beutler
Journal:  Lancet       Date:  1989-08-12       Impact factor: 79.321

4.  A new glucocerebrosidase-gene missense mutation responsible for neuronopathic Gaucher disease in Japanese patients.

Authors:  H Kawame; Y Eto
Journal:  Am J Hum Genet       Date:  1991-12       Impact factor: 11.025

5.  Complex alleles of the acid beta-glucosidase gene in Gaucher disease.

Authors:  T Latham; G A Grabowski; B D Theophilus; F I Smith
Journal:  Am J Hum Genet       Date:  1990-07       Impact factor: 11.025

Review 6.  Gaucher disease in the neonate: a distinct Gaucher phenotype is analogous to a mouse model created by targeted disruption of the glucocerebrosidase gene.

Authors:  E Sidransky; D M Sherer; E I Ginns
Journal:  Pediatr Res       Date:  1992-10       Impact factor: 3.756

7.  Rapid identification of mutations in the glucocerebrosidase gene of Gaucher disease patients by analysis of single-strand conformation polymorphisms.

Authors:  H Kawame; Y Hasegawa; Y Eto; K Maekawa
Journal:  Hum Genet       Date:  1992-11       Impact factor: 4.132

8.  Gaucher disease type III (Norrbottnian type) is caused by a single mutation in exon 10 of the glucocerebrosidase gene.

Authors:  N Dahl; M Lagerström; A Erikson; U Pettersson
Journal:  Am J Hum Genet       Date:  1990-08       Impact factor: 11.025

9.  Non-existence of a tight association between a 444leucine to proline mutation and phenotypes of Gaucher disease: high frequency of a NciI polymorphism in the non-neuronopathic form.

Authors:  M Masuno; S Tomatsu; K Sukegawa; T Orii
Journal:  Hum Genet       Date:  1990-01       Impact factor: 4.132

10.  Identification of the second common Jewish Gaucher disease mutation makes possible population-based screening for the heterozygous state.

Authors:  E Beutler; T Gelbart; W Kuhl; J Sorge; C West
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

View more
  14 in total

1.  Mechanism of glucocerebrosidase activation and dysfunction in Gaucher disease unraveled by molecular dynamics and deep learning.

Authors:  Raquel Romero; Arvind Ramanathan; Tony Yuen; Debsindhu Bhowmik; Mehr Mathew; Lubna Bashir Munshi; Seher Javaid; Madison Bloch; Daria Lizneva; Alina Rahimova; Ayesha Khan; Charit Taneja; Se-Min Kim; Li Sun; Maria I New; Shozeb Haider; Mone Zaidi
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-26       Impact factor: 11.205

2.  Gaucher disease: the origins of the Ashkenazi Jewish N370S and 84GG acid beta-glucosidase mutations.

Authors:  G A Diaz; B D Gelb; N Risch; T G Nygaard; A Frisch; I J Cohen; C S Miranda; O Amaral; I Maire; L Poenaru; C Caillaud; M Weizberg; P Mistry; R J Desnick
Journal:  Am J Hum Genet       Date:  2000-04-21       Impact factor: 11.025

3.  Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease.

Authors:  V Koprivica; D L Stone; J K Park; M Callahan; A Frisch; I J Cohen; N Tayebi; E Sidransky
Journal:  Am J Hum Genet       Date:  2000-05-04       Impact factor: 11.025

4.  Improvement of splenomegaly and pancytopenia by enzyme replacement therapy against type 1 Gaucher disease: a report of sibling cases.

Authors:  K Tsuboi; S Iida; M Kato; Y Hayami; I Hanamura; K Miura; S Harada; H Komatsu; S Banno; A Wakita; M Nitta; R Ueda
Journal:  Int J Hematol       Date:  2001-04       Impact factor: 2.490

5.  Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry.

Authors:  Anna Tylki-Szymańska; Ashok Vellodi; Amal El-Beshlawy; J Alexander Cole; Edwin Kolodny
Journal:  J Inherit Metab Dis       Date:  2010-01-19       Impact factor: 4.982

Review 6.  Gaucher disease: new developments in treatment and etiology.

Authors:  Ozgur Harmanci; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2008-07-07       Impact factor: 5.742

7.  Mapping the genetic and clinical characteristics of Gaucher disease in the Iberian Peninsula.

Authors:  Pilar Giraldo; Pilar Alfonso; Pilar Irún; Laura Gort; Amparo Chabás; Lluïsa Vilageliu; Daniel Grinberg; Clara M Sá Miranda; Miguel Pocovi
Journal:  Orphanet J Rare Dis       Date:  2012-03-19       Impact factor: 4.123

8.  Type I Gaucher disease with exophthalmos and pulmonary arteriovenous malformation.

Authors:  Chun-An Chen; Nelson L S Tang; Yin-Hsiu Chien; Wei-Min Zhang; Jou-Kou Wang; Wuh-Liang Hwu
Journal:  BMC Med Genet       Date:  2005-06-09       Impact factor: 2.103

9.  Gaucher disease: single gene molecular characterization of one-hundred Indian patients reveals novel variants and the most prevalent mutation.

Authors:  Jayesh Sheth; Riddhi Bhavsar; Mehul Mistri; Dhairya Pancholi; Ashish Bavdekar; Ashwin Dalal; Prajnya Ranganath; Katta M Girisha; Anju Shukla; Shubha Phadke; Ratna Puri; Inusha Panigrahi; Anupriya Kaur; Mamta Muranjan; Manisha Goyal; Radha Ramadevi; Raju Shah; Sheela Nampoothiri; Sumita Danda; Chaitanya Datar; Seema Kapoor; Seema Bhatwadekar; Frenny Sheth
Journal:  BMC Med Genet       Date:  2019-02-14       Impact factor: 2.103

10.  The French Gaucher's disease registry: clinical characteristics, complications and treatment of 562 patients.

Authors:  Jérôme Stirnemann; Marie Vigan; Dalil Hamroun; Djazia Heraoui; Linda Rossi-Semerano; Marc G Berger; Christian Rose; Fabrice Camou; Christine de Roux-Serratrice; Bernard Grosbois; Pierre Kaminsky; Alain Robert; Catherine Caillaud; Roselyne Froissart; Thierry Levade; Agathe Masseau; Cyril Mignot; Frédéric Sedel; Dries Dobbelaere; Marie T Vanier; Vassili Valayanopoulos; Olivier Fain; Bruno Fantin; Thierry Billette de Villemeur; France Mentré; Nadia Belmatoug
Journal:  Orphanet J Rare Dis       Date:  2012-10-09       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.